. 2021 Apr 5;4(3):1195–1203. doi: 10.1021/acsptsci.1c00062

Table 1. 9L, U87 ΔEGFR, and DU145 Cell Uptake of [¹⁸F]5 with and without Inhibitors after 30 min of Incubation^a.

tumor cell line		[¹⁸F]5	% inhibition
9L	control	23.5 ± 1.5
	BCH	3.91 ± 0.72*	83
	MeAIB	24.8 ± 2.3**	no inhibition
	ASC	11.1 ± 0.54*	53
U87 ΔEGFR	control	6.45 ± 0.46
	BCH	2.16 ± 0.11*	67
	MeAIB	5.47 ± 0.16**	no inhibition
	ASC	2.34 ± 0.18*	64
DU145	control	34.0 ± 4.1
	BCH	2.03 ± 0.19*	94
	MeAIB	31.9 ± 1.4**	7
	ASC	5.68 ± 0.60*	83

Data are presented as percent ligand uptake of the initial dose per 0.5 million cells (%ID/5 × 10⁵ cells) ± standard deviation (n = 3–4) and normalized for the dose and number of cells. p-Values represent comparisons of uptake in the presence of inhibitor to control uptake using two-tailed paired t-tests. p < 0.05 is considered statistically significant. *p < 0.05. **p ≥ 0.05.

Table 1. 9L, U87 ΔEGFR, and DU145 Cell Uptake of [18F]5 with and without Inhibitors after 30 min of Incubationa.

Table 1. 9L, U87 ΔEGFR, and DU145 Cell Uptake of [¹⁸F]5 with and without Inhibitors after 30 min of Incubation^a.